Drugs in the Pipeline
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.
Drugs in the Pipeline
Following clearance of an Investigational New Drug Application by the Food and Drug Administration, ViralClear announced that a phase 2 study evaluating merimepodib oral solution for the treatment of coronavirus disease 2019 (COVID-19) will be initiated.
Drugs in the Pipeline
Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.
Drugs in the Pipeline, News
The FDA has approved the Investigational New Drug (IND) application for the phase 2a study of opaganib (RedHill Biopharma) in patients with confirmed moderate to severe SARS-CoV-2 infection.
Drugs in the Pipeline
Updated on 6/16 While no specific treatment for coronavirus disease 2019 (COVID-19) is currently available, several therapies are being investigated globally.* AB201 (ARCA biopharma): a selective inhibitor of tissue factor being developed as a potential treatment for COVID associated coagulopathy. Clinical testing is expected to begin in the second half of 2020. Acalabrutinib (AstraZeneca): a…
Drugs in the Pipeline
Currently, there are no antivirals licensed by the FDA to treat patients with COVID-19.
Drugs in the Pipeline
FibroGen announced data from its Phase 2a study of FG-4592 (oral anemia therapy) in patients with stage 3-4 chronic kidney disease (CKD) and anemia.
